2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3003

Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells, and Immune Cells
Abstract Number: 3011

Ambulatory Gait Analysis in Clinical Practice: Single or Dual Task Conditions?
Abstract Number: 1986

Ambulatory Rheumatology Curriculum: Effect of Multimodal Curriculum Enhancement
Abstract Number: 2344

Amelioration of Collagen-Induced Arthritis By Water-Soluble Fullerene C60(OH)₃₆ Nanoparticles through the Inhibition of Angiogenesis
Abstract Number: 934

Amelioration of Inflammatory Arthritis By Anti-TNF Therapy Is Associated with Restoration of Lymphatic Contraction
Abstract Number: 857

Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors
Abstract Number: 84

Amerindian Ancestry Influences Polyautoimmunity
Abstract Number: 2039

Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Abstract Number: 2888

Amount of Smoking, Duration of Smoking Cessation, and Their Interaction with Silica Exposure in the Risk of Rheumatoid Arthritis: Results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study
Abstract Number: 327

AMPK Activation in Inflammatory Arthritis
Abstract Number: 221

An Analysis of Age-Related Loss of Skeletal Muscle Mass and Its Significance on Osteoarthritis in a Korean Population
Abstract Number: 1514

An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
Abstract Number: 1757

An Analysis of the Incidence and Characteristics of ANCA Positive Vasculitis before and after the Christchurch Earthquake
Abstract Number: 2842

An Anti CD123 Monoclonal Antibody (CSL362) Depletes Plasmacytoid Dendritic Cells and Inhibits CpG Upregulated IFNα Production and IFNα-Inducible Gene Expression in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
Abstract Number: 1703

An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].